Taro Pharmaceutical Industries Stock

Taro Pharmaceutical Industries ROA 2025

Taro Pharmaceutical Industries ROA

0.02

Ticker

TARO

ISIN

IL0010827181

WKN

897505

In 2025, Taro Pharmaceutical Industries's return on assets (ROA) was 0.02, a 109.47% increase from the 0.01 ROA in the previous year.

Taro Pharmaceutical Industries Aktienanalyse

What does Taro Pharmaceutical Industries do?

Taro Pharmaceutical Industries Ltd. is a company that focuses on generic and specialized pharmaceutical products. The company was founded in Israel in 1950 and has since relocated its headquarters to Ireland. Taro Pharmaceutical has become one of the largest providers of generics and specialty drugs over the years due to its extensive experience, high-quality products, and ability to adapt to changing market conditions. The business model of Taro Pharmaceutical Industries is extremely simple. They offer affordable generic medications. The company's focus is on developing, manufacturing, and distributing generic products on the global market. Taro also has a wide range of specialty drugs, including dermatological and ophthalmology products. Taro Pharmaceutical Industries Ltd.'s business activities are divided into two divisions: Farmaceutica Taro, which specializes in the development, manufacturing, and distribution of generics and specialty drugs, and Taro Research & Development Center, which focuses on researching and developing new medications and generic products. Taro Pharmaceutical Industries Ltd. offers a wide range of products, including tablets, ointments, and eye drops. The company provides a variety of products in various therapeutic areas such as dermatology, cardiology, urology, gynecology, neurology, pediatrics, gastroenterology, and infectious diseases. The dermatological products of Taro Pharmaceutical, such as Clobetasol Propionate Cream and Lidocaine, are known for their effectiveness in skincare. With its eye products like Dorzolamide and Timolol Maleate Ophthalmic Solution, the company focuses on the ophthalmology field. Taro also produces medications that help with cardiovascular diseases, such as Amlodipine and Enalapril. Taro Pharmaceutical Industries Ltd. was founded in 1950 by chemist George Rosenberg and his partner Leo Ringer in Haifa, Israel. Manufacturing of pharmaceutical ingredients for drug production began in 1951. The company has been focused on growth since its inception and has built a strong reputation for its production quality. In 1969, Taro Pharmaceutical went public with a market capitalization of approximately 8 million US dollars. Over the years, the company expanded its portfolio and grew rapidly through acquisitions of other companies and expansion into international locations such as Canada, Switzerland, Mexico, Spain, and Italy. Taro Pharmaceutical was sold to Italian pharma company Ariston in 1993 and acquired by Indian pharma company Sun Pharmaceutical Industries in 2013. The company's headquarters is now in Dublin, Ireland, and it produces for markets worldwide, including North America, Europe, Asia, Australia, and South America. In conclusion, Taro Pharmaceutical Industries is one of the leading companies in the generic production field and has become a strong player in the specialized pharmaceutical products sector. The company has proven its expertise in research and development, manufacturing, and distribution of sought-after products. With the global demand for medications expected to continue rising, a company like Taro, which offers sustainable and affordable preventive solutions, plays an important role in the healthcare industry and will continue to do so in the future. Taro Pharmaceutical Industries ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Taro Pharmaceutical Industries's Return on Assets (ROA)

Taro Pharmaceutical Industries's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Taro Pharmaceutical Industries's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Taro Pharmaceutical Industries's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Taro Pharmaceutical Industries’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Taro Pharmaceutical Industries stock

What is the Return on Assets (ROA) of Taro Pharmaceutical Industries this year?

The Return on Assets (ROA) of Taro Pharmaceutical Industries is 0.02 undefined this year.

What was the ROA of Taro Pharmaceutical Industries compared to the previous year?

The ROA of Taro Pharmaceutical Industries has increased by 109.47% compared to the previous year.

What consequences do high ROA have for investors of Taro Pharmaceutical Industries?

A high ROA is advantageous for investors of Taro Pharmaceutical Industries, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Taro Pharmaceutical Industries?

A low ROA can be unfavorable for investors of Taro Pharmaceutical Industries as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Taro Pharmaceutical Industries affect the company?

An increase in ROA of Taro Pharmaceutical Industries can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Taro Pharmaceutical Industries impact the company?

A reduction in the ROA of Taro Pharmaceutical Industries can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Taro Pharmaceutical Industries?

Some factors that can influence the ROA of Taro Pharmaceutical Industries include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Taro Pharmaceutical Industries important for investors?

The ROA of Taro Pharmaceutical Industries is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Taro Pharmaceutical Industries take to improve ROA?

To improve ROA, Taro Pharmaceutical Industries can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Taro Pharmaceutical Industries pay?

Over the past 12 months, Taro Pharmaceutical Industries paid a dividend of 12.86 USD . This corresponds to a dividend yield of about 29.93 %. For the coming 12 months, Taro Pharmaceutical Industries is expected to pay a dividend of 0 USD.

What is the dividend yield of Taro Pharmaceutical Industries?

The current dividend yield of Taro Pharmaceutical Industries is 29.93 %.

When does Taro Pharmaceutical Industries pay dividends?

Taro Pharmaceutical Industries pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries paid dividends every year for the past 1 years.

What is the dividend of Taro Pharmaceutical Industries?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Taro Pharmaceutical Industries located?

Taro Pharmaceutical Industries is assigned to the 'Health' sector.

Wann musste ich die Aktien von Taro Pharmaceutical Industries kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Taro Pharmaceutical Industries from 12/28/2018 amounting to 12.86 USD, you needed to have the stock in your portfolio before the ex-date on 12/10/2018.

When did Taro Pharmaceutical Industries pay the last dividend?

The last dividend was paid out on 12/28/2018.

What was the dividend of Taro Pharmaceutical Industries in the year 2024?

In the year 2024, Taro Pharmaceutical Industries distributed 0 USD as dividends.

In which currency does Taro Pharmaceutical Industries pay out the dividend?

The dividends of Taro Pharmaceutical Industries are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Taro Pharmaceutical Industries

Our stock analysis for Taro Pharmaceutical Industries Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Taro Pharmaceutical Industries Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.